Ranitidine Hydrochloride

This chemical does not meet GHS hazard criteria for 3.9% (3 of 76) of reports.

Danger

H315 (85.5%): Causes skin irritation [Warning Skin corrosion/irritation]；H317 (93.4%): May cause an allergic skin reaction [Warning Sensitization, Skin]；H319 (86.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H334 (92.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]；H335 (92.1%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 76 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Reported as not meeting GHS hazard criteria per 3 of 76 reports by companies.；There are 12 notifications provided by 73 of 76 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Allergic contact dermatitis reported in pharmaceutical workers; [Kanerva, p. 1170] Ranitidine is a drug to reduce acid secretion in the stomach. Many side effects have been reported after ingestion of therapeutic doses including, rarely, drug-induced hepatitis. [HSDB]

Skin Irrit. 2 (100%)；Skin Sens. 1 (100%)；Eye Irrit. 2 (100%)；Resp. Sens. 1 (96.3%)；STOT SE 3 (100%)

Skin Irrit. 2 (85.5%)；Skin Sens. 1 (93.4%)；Eye Irrit. 2 (86.8%)；Resp. Sens. 1 (92.1%)；STOT SE 3 (92.1%)

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.；Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ranitidine hydrochloride

vLess-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

◉ Summary of Use during Lactation；Although interpatient variability exists, the dose of ranitidine in breastmilk is less than the dose used in newborn infants. Ranitidine itself is not a concern during breastfeeding, but it can break down to a toxic compound if not formulated and stored properly. An alternate drug might be preferred.；◉ Effects in Breastfed Infants；One 54-day-old breastfed infant had no observable adverse effects after maternal ingestion of ranitidine 150 mg every 12 hours for 2 days.；◉ Effects on Lactation and Breastmilk；Histamine H2-receptor blockade is known to stimulate prolactin secretion. Ranitidine in intravenous doses over 100 mg or during long-term oral use have increased serum prolactin in some studies, and rare cases of gynecomastia have been reported. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

RANITIDINE HYDROCHLORIDE

Histamine-2 Receptor Antagonist [EPC]; Histamine H2 Receptor Antagonists [MoA]

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.

Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.

Use (kg) in Switzerland (2009): >1000；Use (kg; approx.) in Germany (2009): >25000；Use (kg) in USA (2002): 86700；Use (kg) in France (2004): 11656；Consumption (g per capita) in Switzerland (2009): 0.13；Consumption (g per capita; approx.) in Germany (2009): 0.31；Consumption (g per capita) in the USA (2002): 0.31；Consumption (g per capita) in France (2004): 0.19；Excretion rate: 0.3；Calculated removal (%): 22